Management of Recurrent Purulent Scrotal Abscess Due to MRSA
For a recurrent purulent scrotal abscess at the same site two months after initial MRSA treatment, immediate surgical incision and drainage is the definitive primary therapy, followed by systemic antibiotics active against MRSA—specifically oral trimethoprim-sulfamethoxazole (TMP-SMX) 1–2 double-strength tablets twice daily or clindamycin 300–450 mg every 6 hours for 7–10 days, combined with aggressive decolonization measures (intranasal mupirocin and chlorhexidine body washes) to prevent further recurrence. 1, 2
Immediate Surgical Management
- Incision and drainage (I&D) is the cornerstone of therapy for any purulent collection and must be performed whenever feasible; antibiotics alone will fail without adequate source control. 1, 2
- Obtain cultures from purulent drainage before initiating antibiotics to confirm MRSA and guide definitive therapy, especially given the history of prior MRSA infection at this site. 2
- Ensure complete drainage of all loculated pockets; inadequate I&D is the most common cause of treatment failure regardless of antibiotic choice. 1, 3
Systemic Antibiotic Therapy
Outpatient Oral Regimens (if no systemic toxicity)
- Trimethoprim-sulfamethoxazole (TMP-SMX) 1–2 double-strength tablets (160–320/800–1600 mg) orally twice daily for 7–10 days is the preferred first-line oral agent for recurrent MRSA skin abscesses. 2, 4
- Clindamycin 300–450 mg orally every 6 hours is an alternative single-agent option that covers both MRSA and streptococci, but should only be used if local MRSA clindamycin resistance rates are <10%. 1, 2, 4
- Canadian pooled clindamycin resistance exceeds 40%, making TMP-SMX the safer empiric choice in many regions. 5
- Doxycycline 100 mg orally twice daily or minocycline 100 mg orally twice daily are effective alternatives for MRSA skin infections. 2
- Linezolid 600 mg orally twice daily is reserved for complicated cases or when other oral agents cannot be used. 2
Intravenous Therapy (if systemic toxicity, extensive disease, or outpatient failure)
- Vancomycin 15–20 mg/kg IV every 8–12 hours (targeting trough 15–20 mg/L) is the first-line IV agent for complicated MRSA infections. 1, 2
- Daptomycin 4–6 mg/kg IV once daily is an equally effective alternative with A-I level evidence. 2
- Linezolid 600 mg IV twice daily is another option with proven efficacy in MRSA skin and soft tissue infections. 2
Treatment Duration
- For recurrent abscesses with adequate drainage, treat for 7–10 days; extend to 7–14 days for complicated infections involving deeper tissues or multiple sites. 2, 4
- The initial 5-day course recommended for uncomplicated first-time abscesses is insufficient for recurrent disease at the same site. 1
Decolonization to Prevent Further Recurrence
- Implement decolonization with intranasal mupirocin 2% ointment twice daily for 5–10 days plus daily chlorhexidine body washes to eradicate MRSA colonization and reduce recurrent infections. 2
- Keep draining wounds covered with clean, dry bandages and maintain rigorous hand hygiene with soap and water or alcohol-based gel. 2
- Avoid sharing personal items (towels, razors, clothing) that may harbor MRSA. 2
- Evaluate and potentially treat household contacts if recurrent infections persist despite decolonization efforts. 2
Special Considerations for Scrotal Location
- Fournier gangrene (necrotizing fasciitis of the scrotum and perineum) must be excluded in any scrotal infection, particularly with rapid progression, severe pain out of proportion to examination, skin necrosis, crepitus, or systemic toxicity. 1, 6
- If necrotizing infection is suspected, initiate broad-spectrum combination therapy immediately: vancomycin 15–20 mg/kg IV every 8–12 hours plus piperacillin-tazobactam 3.375–4.5 g IV every 6 hours, and obtain emergent surgical consultation for diagnostic and therapeutic debridement. 1
- The testes, glans penis, and spermatic cord are typically spared in Fournier gangrene because they have a separate blood supply, but the infection may extend to the perineum and anterior abdominal wall. 1
Hospitalization Criteria
Admit patients with recurrent scrotal abscess when any of the following are present:
- Systemic inflammatory response syndrome (fever >38°C, tachycardia >90 bpm, tachypnea >24 breaths/min). 1, 2
- Signs of necrotizing infection (severe pain disproportionate to findings, skin anesthesia, rapid progression, "wooden-hard" tissue, gas or bullae). 1
- Multiple infection sites or extensive surrounding cellulitis. 2
- Immunocompromise, diabetes, or other significant comorbidities. 2
- Failure of outpatient therapy after 48–72 hours. 1
Critical Pitfalls to Avoid
- Do not prescribe beta-lactam antibiotics (cephalexin, dicloxacillin, amoxicillin-clavulanate) for MRSA coverage; the mecA gene encoding PBP2a confers resistance to all beta-lactams. 2
- Do not rely on antibiotics alone without adequate I&D; drainage is the definitive primary treatment, and antibiotics serve only an adjunctive role. 1, 2, 3
- Do not use fluoroquinolones as monotherapy for MRSA due to high resistance rates. 2
- Do not delay surgical consultation if any signs of necrotizing infection are present; these infections progress rapidly and require immediate debridement. 1
- Do not neglect decolonization measures in recurrent MRSA infections; failure to eradicate colonization leads to repeated episodes. 2
Monitoring and Follow-Up
- Reassess clinically at 48–72 hours after initiating therapy to ensure adequate response. 2
- If no improvement after 48–72 hours of appropriate therapy, consider: inadequate drainage requiring repeat procedure, infection with a resistant organism (obtain repeat cultures), deeper infection such as necrotizing fasciitis, or an alternative diagnosis. 1, 2
- Repeat blood cultures 2–4 days after initial positive cultures if bacteremia is documented to confirm clearance. 2